Literature DB >> 20835264

Simvastatin inhibited cardiac hypertrophy and fibrosis in apolipoprotein E-deficient mice fed a "Western-style diet" by increasing PPAR α and γ expression and reducing TC, MMP-9, and Cat S levels.

Yan-wen Qin1, Ping Ye, Ji-qiang He, Li Sheng, Lu-ya Wang, Jie Du.   

Abstract

AIM: The examine the cardiac hypertrophy and fibrosis in apolipoprotein E-deficient mice (ApoE-/- mice) fed a "Western-style diet" and the effect of simvastatin intervention.
METHODS: Male ApoE-/- mice (n=36) were fed a "Western-style diet" from the age of 8 weeks. After 16 weeks, they were randomly given either simvastatin (25 mg·kg⁻¹·d⁻¹) or normal saline (control group) by gavage for 8, 16, or 24 weeks. The left ventricular (LV) wall thickness and diameter of the myocardial cells were determined with Hematoxylin-Eosin stain, and the level of fibrosis of the myocardial matrix was assessed with Masson stain. Real-time quantitative polymerase chain reaction and Western blotting analysis were used to determine the mRNA and protein expression of matrix metalloproteinase-9 (MMP-9), Cathepsin S (Cat S), and the peroxisome proliferator-activated receptors (PPARs) in the myocardium of ApoE-/- mice.
RESULTS: ApoE-/- mice fed a "Western-style diet" showed an significant age-dependent increase in total cholesterol (TC), LV wall thickness, myocardial cell diameter and LV collagen content (P<0.05). The simvastatin treatment group showed significantly reduced LV wall thickness, myocardial cell diameters and LV collagen content at 40 weeks when compared with the control group (P<0.05). Furthermore, treatment with simvastatin also significantly inhibited the mRNA and protein expressions of MMP-9 and Cat S as well as increased the mRNA and protein expressions of PPAR alpha and PPAR gamma at 32 and 40 weeks compared with the control group (P<0.05).
CONCLUSION: ApoE-/- mice fed a "Western-style diet" had cardiac hypertrophy and fibrosis, which worsened with age. Simvastatin treatment inhibits the development of cardiac hypertrophy and fibrosis, and this effect may be mediated through increased levels of PPAR alpha and PPAR gamma and reduced levels of TC, MMP-9, and Cat S.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20835264      PMCID: PMC4012913          DOI: 10.1038/aps.2010.109

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  27 in total

1.  Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy.

Authors:  M Takemoto; K Node; H Nakagami; Y Liao; M Grimm; Y Takemoto; M Kitakaze; J K Liao
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

2.  Aortic constriction exacerbates atherosclerosis and induces cardiac dysfunction in mice lacking apolipoprotein E.

Authors:  Jiao-Hui Wu; John Hagaman; Shinja Kim; Robert L Reddick; Nobuyo Maeda
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-03-01       Impact factor: 8.311

3.  Association of pravastatin and left ventricular mass in hypercholesterolemic patients: role of 8-iso-prostaglandin f2alpha formation.

Authors:  Tsung-Ming Lee; Tsai-Fwu Chou; Chang-Her Tsai
Journal:  J Cardiovasc Pharmacol       Date:  2002-12       Impact factor: 3.105

Review 4.  Cardiovascular functional phenotypes and pharmacological responses in apolipoprotein E deficient mice.

Authors:  Yi-Xin Wang
Journal:  Neurobiol Aging       Date:  2005-03       Impact factor: 4.673

5.  Dyslipidemia and an unfavorable fatty acid profile predict left ventricular hypertrophy 20 years later.

Authors:  J Sundström; L Lind; B Vessby; B Andrén; A Aro; H Lithell
Journal:  Circulation       Date:  2001-02-13       Impact factor: 29.690

Review 6.  Molecular targets and regulators of cardiac hypertrophy.

Authors:  Agrawal Rohini; Neeraj Agrawal; Chintan N Koyani; Randhir Singh
Journal:  Pharmacol Res       Date:  2009-12-05       Impact factor: 7.658

7.  ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree.

Authors:  Y Nakashima; A S Plump; E W Raines; J L Breslow; R Ross
Journal:  Arterioscler Thromb       Date:  1994-01

Review 8.  A novel pleiotropic effect of statins: prevention of cardiac hypertrophy by cholesterol-independent mechanisms.

Authors:  Hironori Nakagami; Kristin S Jensen; James K Liao
Journal:  Ann Med       Date:  2003       Impact factor: 4.709

Review 9.  Role of matrix metalloproteinases in hypertension-associated cardiac fibrosis.

Authors:  Begoña López; Arantxa González; Javier Díez
Journal:  Curr Opin Nephrol Hypertens       Date:  2004-03       Impact factor: 2.894

10.  Increased expression of elastolytic cysteine proteases, cathepsins S and K, in the neointima of balloon-injured rat carotid arteries.

Authors:  Xian Wu Cheng; Masafumi Kuzuya; Takeshi Sasaki; Koji Arakawa; Shigeru Kanda; Daigo Sumi; Teruhiko Koike; Keiko Maeda; Norika Tamaya-Mori; Guo-Ping Shi; Noboru Saito; Akihisa Iguchi
Journal:  Am J Pathol       Date:  2004-01       Impact factor: 4.307

View more
  26 in total

1.  Frontiers of vascular biology and disease research.

Authors:  Alex F Chen; Chao-shu Tang
Journal:  Acta Pharmacol Sin       Date:  2010-10       Impact factor: 6.150

Review 2.  Interplay between statins and PPARs in improving cardiovascular outcomes: a double-edged sword?

Authors:  Pitchai Balakumar; Nanjaian Mahadevan
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

3.  Differentially expressed genes in human peripheral blood as potential markers for statin response.

Authors:  Hong-Hee Won; Suk Ran Kim; Oh Young Bang; Sang-Chol Lee; Wooseong Huh; Jae-Wook Ko; Hyung-Gun Kim; Howard L McLeod; Thomas M O'Connell; Jong-Won Kim; Soo-Youn Lee
Journal:  J Mol Med (Berl)       Date:  2011-09-24       Impact factor: 4.599

4.  Modulation of cholesterol-related gene expression by ergosterol and ergosterol-enriched extracts obtained from Agaricus bisporus.

Authors:  Alicia Gil-Ramírez; Víctor Caz; Roberto Martin-Hernandez; Francisco R Marín; Carlota Largo; Arantxa Rodríguez-Casado; María Tabernero; Alejandro Ruiz-Rodríguez; Guillermo Reglero; Cristina Soler-Rivas
Journal:  Eur J Nutr       Date:  2015-05-07       Impact factor: 5.614

5.  Effect of rosuvastatin on atrial structural remodeling in rabbits with myocardial infarction.

Authors:  Weijie Wang; Yujiao Zhang; Mei Gao; Jiangrong Wang; Yinglong Hou
Journal:  Biomed Rep       Date:  2014-09-26

6.  Original Research: Atorvastatin prevents rat cardiomyocyte hypertrophy induced by parathyroid hormone 1-34 associated with the Ras-ERK signaling.

Authors:  Xiaogang Liu; Chunbo Zou; Chengyuan Yu; Rujuan Xie; Manshu Sui; Suhong Mu; Li Li; Shilei Zhao
Journal:  Exp Biol Med (Maywood)       Date:  2016-05-10

7.  Early changes of plasma angiopoietin-2 in patients with multiple trauma.

Authors:  Hai-Bin Weng; Sen Li
Journal:  World J Emerg Med       Date:  2011

8.  Inflammatory stress exacerbates the progression of cardiac fibrosis in high-fat-fed apolipoprotein E knockout mice via endothelial-mesenchymal transition.

Authors:  Kun Ling Ma; Jing Liu; Jie Ni; Yang Zhang; Lin Li Lv; Ri Ning Tang; Hai Feng Ni; Xiong Zhong Ruan; Bi Cheng Liu
Journal:  Int J Med Sci       Date:  2013-02-28       Impact factor: 3.738

9.  Docosahexaenoic acid supplementation does not improve Western diet-induced cardiomyopathy in rats.

Authors:  Kimberly M Jeckel; D N Rao Veeramachaneni; Adam J Chicco; Phillip L Chapman; Christopher M Mulligan; Jennifer R Hegarty; Michael J Pagliassotti; Lindsay A Ferguson; Gerrit J Bouma; Melinda A Frye
Journal:  PLoS One       Date:  2012-12-26       Impact factor: 3.240

Review 10.  Cardiac and vascular phenotypes in the apolipoprotein E-deficient mouse.

Authors:  Elisardo C Vasquez; Veronica A Peotta; Agata L Gava; Thiago Mc Pereira; Silvana S Meyrelles
Journal:  J Biomed Sci       Date:  2012-02-13       Impact factor: 8.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.